CN104093742A - 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体 - Google Patents

抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体 Download PDF

Info

Publication number: CN104093742A
Authority: CN; China
Prior art keywords: antibody; her3; fragment; structural domain; sequence
Prior art date: 2011-12-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201280068966.8A

Other languages

English (en)

Chinese (zh)

Inventor

W·埃利斯

S·埃滕伯格

A·P·加纳

N·豪布斯特

H·于埃

C·C·S·昆茨

E·A·赖辛格斯普拉格

Q·盛

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-05

Filing date

2012-12-04

Publication date

2014-10-08

2012-12-04 Application filed by Novartis AG filed Critical Novartis AG

2014-10-08 Publication of CN104093742A publication Critical patent/CN104093742A/zh

Status Pending legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Neurology (AREA)
Dermatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN201280068966.8A 2011-12-05 2012-12-04 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体 Pending CN104093742A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161566912P	2011-12-05	2011-12-05
US61/566,912		2011-12-05
PCT/IB2012/056956 WO2013084151A2 (en)	2011-12-05	2012-12-04	Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3

Publications (1)

Publication Number	Publication Date
CN104093742A true CN104093742A (zh)	2014-10-08

Family

ID=47561692

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201280068966.8A Pending CN104093742A (zh)	2011-12-05	2012-12-04	抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体

Country Status (16)

Country	Link
EP (1)	EP2788381A2 (ja)
JP (1)	JP2015500830A (ja)
KR (1)	KR20140099315A (ja)
CN (1)	CN104093742A (ja)
AR (1)	AR089085A1 (ja)
AU (1)	AU2012349739A1 (ja)
BR (1)	BR112014013495A2 (ja)
CA (1)	CA2857939A1 (ja)
EA (1)	EA201491120A1 (ja)
IL (1)	IL232950A0 (ja)
IN (1)	IN2014CN04374A (ja)
MX (1)	MX2014006731A (ja)
SG (1)	SG11201402784WA (ja)
TW (1)	TW201331225A (ja)
UY (1)	UY34488A (ja)
WO (1)	WO2013084151A2 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104530237A (zh) *	2014-12-31	2015-04-22	百泰生物药业有限公司	抗Her1的治疗性抗体
CN110167968A (zh) *	2016-09-15	2019-08-23	斯图加特大学	针对her3的抗原结合蛋白

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ724013A (en)	2014-02-28	2019-11-29	Merus Nv	Antibodies that bind egfr and erbb3
AU2015223567B2 (en) *	2014-02-28	2020-09-10	Merus N.V.	Antibody that binds ErbB-2 and ErbB-3
WO2016011167A1 (en)	2014-07-16	2016-01-21	Dana-Farber Cancer Institute, Inc., Et Al	Her3 inhibition in low-grade serous ovarian cancers
MX2018004988A (es)	2015-10-23	2018-11-09	Merus Nv	Moleculas de union que inhibe el crecimiento de cancer.
JP6729926B2 (ja) *	2016-05-12	2020-07-29	国立大学法人神戸大学	ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法
KR101923641B1 (ko) *	2016-11-25	2018-11-29	재단법인 목암생명과학연구소	항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2018182422A1 (en)	2017-03-31	2018-10-04	Merus N.V.	Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11202001050PA (en)	2017-08-09	2020-03-30	Merus Nv	Antibodies that bind egfr and cmet

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007077028A2 (en) *	2005-12-30	2007-07-12	U3 Pharma Ag	Antibodies directed to her-3 and uses thereof
WO2010127181A1 (en) *	2009-04-29	2010-11-04	Trellis Bioscience, Inc.	Improved antibodies immunoreactive with heregulin-coupled her3
WO2011060206A2 (en) *	2009-11-13	2011-05-19	U3 Pharma Gmbh	Material and methods for treating or preventing her-3 associated diseases
WO2011136911A2 (en) *	2010-04-09	2011-11-03	Aveo Pharmaceuticals, Inc.	Anti-erbb3 antibodies
WO2012031198A2 (en) *	2010-09-03	2012-03-08	Glaxo Group Limited	Novel antigen binding proteins
WO2012156309A1 (en) *	2011-05-13	2012-11-22	Millegen	Antibodies against her3
WO2013016714A1 (en) *	2011-07-28	2013-01-31	Sea Lane Biotechnologies	Sur-binding proteins against erbb3

2012
- 2012-12-04 WO PCT/IB2012/056956 patent/WO2013084151A2/en active Application Filing
- 2012-12-04 MX MX2014006731A patent/MX2014006731A/es unknown
- 2012-12-04 SG SG11201402784WA patent/SG11201402784WA/en unknown
- 2012-12-04 IN IN4374CHN2014 patent/IN2014CN04374A/en unknown
- 2012-12-04 UY UY0001034488A patent/UY34488A/es not_active Application Discontinuation
- 2012-12-04 TW TW101145508A patent/TW201331225A/zh unknown
- 2012-12-04 AU AU2012349739A patent/AU2012349739A1/en not_active Abandoned
- 2012-12-04 EA EA201491120A patent/EA201491120A1/ru unknown
- 2012-12-04 KR KR1020147018336A patent/KR20140099315A/ko not_active Application Discontinuation
- 2012-12-04 JP JP2014545420A patent/JP2015500830A/ja active Pending
- 2012-12-04 BR BR112014013495A patent/BR112014013495A2/pt not_active Application Discontinuation
- 2012-12-04 CN CN201280068966.8A patent/CN104093742A/zh active Pending
- 2012-12-04 EP EP12816130.4A patent/EP2788381A2/en not_active Withdrawn
- 2012-12-04 CA CA2857939A patent/CA2857939A1/en not_active Abandoned
- 2012-12-05 AR ARP120104559A patent/AR089085A1/es unknown
2014
- 2014-06-02 IL IL232950A patent/IL232950A0/en unknown

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007077028A2 (en) *	2005-12-30	2007-07-12	U3 Pharma Ag	Antibodies directed to her-3 and uses thereof
WO2010127181A1 (en) *	2009-04-29	2010-11-04	Trellis Bioscience, Inc.	Improved antibodies immunoreactive with heregulin-coupled her3
WO2011060206A2 (en) *	2009-11-13	2011-05-19	U3 Pharma Gmbh	Material and methods for treating or preventing her-3 associated diseases
WO2011136911A2 (en) *	2010-04-09	2011-11-03	Aveo Pharmaceuticals, Inc.	Anti-erbb3 antibodies
WO2012031198A2 (en) *	2010-09-03	2012-03-08	Glaxo Group Limited	Novel antigen binding proteins
WO2012156309A1 (en) *	2011-05-13	2012-11-22	Millegen	Antibodies against her3
WO2013016714A1 (en) *	2011-07-28	2013-01-31	Sea Lane Biotechnologies	Sur-binding proteins against erbb3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G SALA ET AL.: "An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling", 《ONCOGENE》 *
GABRIELE SCHAEFER ET AL.: "A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies", 《CANCER CELL》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104530237A (zh) *	2014-12-31	2015-04-22	百泰生物药业有限公司	抗Her1的治疗性抗体
CN104530237B (zh) *	2014-12-31	2017-09-05	百泰生物药业有限公司	抗Her1的治疗性抗体
CN110167968A (zh) *	2016-09-15	2019-08-23	斯图加特大学	针对her3的抗原结合蛋白
CN110167968B (zh) *	2016-09-15	2023-11-28	斯图加特大学	针对her3的抗原结合蛋白

Also Published As

Publication number	Publication date
BR112014013495A8 (pt)	2017-06-13
BR112014013495A2 (pt)	2017-06-13
MX2014006731A (es)	2015-06-04
EP2788381A2 (en)	2014-10-15
AR089085A1 (es)	2014-07-30
CA2857939A1 (en)	2013-06-13
WO2013084151A2 (en)	2013-06-13
IL232950A0 (en)	2014-07-31
KR20140099315A (ko)	2014-08-11
EA201491120A1 (ru)	2015-07-30
TW201331225A (zh)	2013-08-01
UY34488A (es)	2013-07-31
AU2012349739A1 (en)	2014-06-26
SG11201402784WA (en)	2014-06-27
JP2015500830A (ja)	2015-01-08
WO2013084151A3 (en)	2014-01-03
IN2014CN04374A (ja)	2015-09-04

Legal Events

Date	Code	Title	Description
2014-10-08	C06	Publication
2014-10-08	PB01	Publication
2014-12-31	C10	Entry into substantive examination
2014-12-31	SE01	Entry into force of request for substantive examination
2017-05-03	WD01	Invention patent application deemed withdrawn after publication
2017-05-03	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20141008

Publication	Publication Date	Title
JP6771002B2 (ja)	2020-10-21	上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
US20210008201A1 (en)	2021-01-14	Antibodies for epidermal growth factor receptor 3 (her3)
CN104105709A (zh)	2014-10-15	抗her3的结构域ii的表皮生长因子受体3(her3)抗体
US7846440B2 (en)	2010-12-07	Antibodies against ErbB3 and uses thereof
CN104093742A (zh)	2014-10-08	抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体